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ABSTRACT 
The de-Glycosylated vitamin D binding protein is a powerful Macrophage Activating Factor (GcMAF) that 
shows multiple biological effects that could be exploited in the immunotherapy of tumours, viral infections 
and autism.  Here we report the observation of a series of clinical cases describing the results obtained 
administering highly purified GcMAF to patients with diverse types of chronic diseases. These are 
heterogeneous and refer to patients with different types of diseases at different stages. In some cases, 
patients underwent other complementary treatments such as stem cell infusion or administration of 
supplements. In patients harbouring tumours, GcMAF treatment was initiated at late stages of tumour 
progression. Therefore, since this is an open-label, non-controlled, retrospective analysis, caution must be 
employed when ascribing cause and effect to any treatment outcome. However, the response to GcMAF was 
robust and certain trends emerge evident. In all cases (n = 7), GcMAF subcutaneous injections were associated 
with improvement of clinical conditions. No adverse side effects were reported. The observation reported here 
confirm and extend the results previously presented by several Authors and open the way to further trials 
aimed at assessing the precise role and indications for GcMAF in the immunotherapy of chronic diseases. 
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1. INTRODUCTION 
It is well assessed that sequential de-glycosylation of 
vitamin D binding protein (also termed Gc-protein) in 
vivo and in vitro leads to the formation of a macrophage 
activating factor (termed GcMAF) that exerts powerful, 
multiple, biological effects. Given the central role of 
immune system in most chronic diseases, it has been 
postulated that GcMAF could prove useful in a variety of 
conditions that are characterized by immunodeficiency or 
immune system dysfunction (Yamamoto et al., 2008a; 
2008b; 2008c; 2009; Bradstreet et al., 2012; Inui et al., 
2013). The approach of targeting the immune system in 
cancer and other chronic conditions has often been 
referred to as “immunotherapy”.  
The beneficial effects observed in the immunotherapy 
of human tumours (Yamamoto et al., 2008a; 2008b; 
2008c; Inui et al., 2013), have been confirmed in 
controlled experiments performed in several laboratories, 
where GcMAF proved effective against tumours 
transplanted into animals (Toyohara et al., 2011;  
Nonaka et al., 2012; Hirota et al., 2013) as well as in 
human cancer cells cultured in vitro (Gregory et al., 2010; 
Pacini et al., 2012a). In addition to the effects on tumour 
cells, we and others demonstrated that GcMAF 
inhibits cancer cell-induced angiogenesis, thus 
depriving the tumour cell mass of the blood, oxygen 
and nutrient supply that it needs to grow and 
metastasize (Kalkunte et al., 2005; Pacini et al., 2011; 
2012a; 2012b). 
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Even though the majority of papers published on 
GcMAF so far, are in the area of clinical and 
experimental oncology, because of its multifaceted 
biological effects, GcMAF seems to be effective also in 
other chronic conditions that are characterized by immune 
dysfunction and systemic inflammation. The theoretical 
usefulness of GcMAF in HIV/AIDS patients was first 
hypothesized in 1994 (Yamamoto et al., 1995) and a study 
published in 2009 after prolonged follow-up, demonstrated 
the effectiveness of GcMAF in restoring the immune 
system in HIV-infected patients (Yamamoto et al., 2009). 
The involvement of GcMAF in the therapy of autism 
is more recent and the first study on this subject was 
published in 2012 describing the effects of GcMAF in 40 
autistic children (Bradstreet et al., 2012), whereas the 
effects of GcMAF in Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome 
(ME/CFS) (Carruthers et al., 2011), albeit presented at 
international conferences on the syndrome (Lapp, 2011) 
have not yet been published. The effects of GcMAF in 
these conditions that involve the immune system as well 
as the central nervous system can be ascribed to the 
recently elucidated GcMAF molecular signalling 
pathway.  
Thus, we recently hypothesized that the effects of 
GcMAF are mediated by cross-talk with the Vitamin D 
Receptor (VDR) and we elucidated the molecular type 
of interaction occurring between these two vitamin D 
binding proteins that belong to the vitamin D axis and 
exert a multiplicity of effects at the cellular and molecular 
level (Ruggiero and Pacini, 2011; Thyer et al., 2013). 
Since the VDR is expressed in a variety of tissues 
including the central nervous system (Harms et al., 2011) 
it can be hypothesized that GcMAF may exert a direct 
effect on neurons as well as an indirect effect of 
rebalancing the immune system that is often dysfunctional 
in autism and ME/CFS.  
At the molecular level, we demonstrated that GcMAF 
stimulates the intracellular signalling pathway belonging 
to the cAMP cascade and this pathway could be 
responsible for the apoptosis of tumour cells induced by 
GcMAF (Pacini et al., 2011).  
The solidity of the scientific results concerning 
GcMAF effects in a variety of diseases and experimental 
systems is witnessed by the number scientific papers 
published by several research groups in the peer-
reviewed literature since the first report on GcMAF in 
1994 (Yamamoto et al., 1994). Because of the solid 
scientific rationale underlying the compassionate use of 
GcMAF in patients with advanced or untreatable 
diseases, hundreds of physicians in all parts of the world 
have adopted its use in a variety of conditions where it 
could prove useful. In this series of clinical cases, we 
report some examples of the results that have been 
obtained administering GcMAF to patients with diverse 
types of cancers at advanced stages and with other 
diseases. In describing the following individual cases, we 
are well aware that these reports, because of their 
heterogeneity and very small numbers, can be considered 
anecdotes. However, it is worth noticing that a very 
recent study on the evaluation of clinical practice 
prompts for re-evaluation of individual cases such as 
those presented here (Nunn, 2011). Thus, it is well 
known that some studies present large and impressive 
statistics obtained from many observations while others 
report a small number of noteworthy events, as we do in 
this study. According to this novel, authoritative, 
epistemological approach, “all of these stories become 
evidence of what works in medicine” (Nunn, 2011). 
Therefore, we suggest that the clinical cases reported 
below may be considered as evidence for the 
effectiveness of GcMAF in different conditions and may 
encourage further studies on this topic. 
2. MATERIALS AND METHODS 
2.1. GcMAF 
Physicians obtained highly purified, commercially 
available GcMAF from Immuno Biotech Ltd., Guernsey, 
Channel Islands. GcMAF was purified according to the 
procedure described by Yamamoto et al. (2008a). 
Briefly, vitamin D-binding protein was isolated from 
purified human serum obtained from the American Red 
Cross, using either 25-hydroxyvitamin D3-Sepharose 
high affinity chromatography, or actin-agarose affinity 
chromatography. The bound material was eluted and 
then further processed by incubation with three 
immobilized enzymes. The resulting GcMAF was filter 
sterilized. The protein content and concentration was 
assayed using standard Bradford protein assay methods 
(Bradford, 1976). At the end of the production process, 
GcMAF was checked for sterility “in-house” and 
externally by independent research laboratories. Its 
safety and biological activity were tested in human 
monocytes (Pacini et al., 2012a), human breast cancer 
cells (Pacini et al., 2012b) and chick embryo 
chorionallantoic membrane (Pacini et al., 2011). Safety 
and activity tests were routinely conducted on each 
individual batch of highly purified GcMAF. 
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2.2. Data Collection 
Data collection consisted in the recollection and 
analysis of the anonymized clinical records and exams 
sent by Physicians who had used GcMAF with their 
patients at the Nova Cells Institute of Mexico (NCIM, La 
Habra Heights, CA, USA). Administration of GcMAF to 
individual patients was performed by their treating 
Physicians according to the rules and regulations of their 
Country. Data collection and analysis were performed at 
Macro Innovations Ltd, Cambridge, UK and at the 
Department of Experimental and Clinical Medicine, 
University of Firenze, Italy. Immuno Biotech Ltd 
provided for data archives and bio-computational 
analysis support. None of the Authors of this study 
treated any of the patients here described. 
Therefore, this study has no characteristics 
whatsoever of a randomized clinical trial; rather, it is a 
retrospective analysis of anonymised reports. The 
Authors left the reports as close as possible to the 
originals with minimal grammar and spelling 
corrections. Since each Practitioner used a different way 
of describing the condition of each individual patient, 
heterogeneity in the reports has to be expected.  
Because of these characteristics, this study has no intent 
of achieving results that could be used to perform statistical 
analyses; the data are purposely presented as raw data so 
that each reader can draw her/his conclusions.  
2.3. Case Reports and Comments 
The following reports were communicated by 
NCIM to Immuno Biotech Ltd and refer to the years 
2012-2013. In addition to GcMAF, most patients were 
prescribed other therapeutic approaches as indicated. 
GcMAF was administered by intramuscular injection 
following the indications outlined in the literature 
(Yamamoto et al., 2008a; 2008b; 2008c). The original 
reports are in italics. 
Patient ID: 001-L.R., 71 Years Male 
Cancer, prostate metastasized to the liver. Came to 
Nova Cells Institute of Mexico July, 2012. Both legs 
swollen up to the thigh. Unable to urinate. No appetite. 
Constipated. Extreme fatigue. Could sit down with 
difficulty because the prostate was enlarged the size of 
an orange. Lots of pain in the lower back, liver and 
prostate. The PSA 345. His overall colour was a pale 
yellow. Before he came to us he was taking anti-
testosterone hormone injection therapy. No chemo or 
radiation. Our doctors stabilized him, drawing 3 quarts of 
urine from his bladder. Gave him enemas and completely 
controlled the inflammation in both his legs. This 
stabilization took 7 days. He was then given our 
treatment which consists of 10 infusions of donor 
granulocytes which have been obtained by the process of 
apheresis from young donors, whose granulocytes are 
very aggressive against cancer cells. One infusion per 
day for 5 days then he rests 2 days and so forth until 
finished. The granulocytes are primed with the NCIM 
proprietary technology. He stayed one month. By the end 
of two weeks he was not jaundiced any more. He had a 
pink colour to his face and palms of his hands and 
enormous appetite. He was given GcMAF twice a week, 
then took the rest home. He injected himself twice a 
week all three vials. He is still injecting more GcMAF 
but only once a week. Three months after his treatment 
with us his PSA was 1. He had no pain, was eating great 
and most astonishing his prostate had shrunken to the 
size of a walnut. His biopsy says no more cancer. 
The results presented in this case are consistent with 
the original study by Yamamoto et al. (2008a) who 
reported that prostate cancer patients treated with 
purified GcMAF were “… tumour-free. No recurrence 
occurred for 7 years” (Yamamoto et al., 2008a). They 
are also consistent with the more recent report by 
Gregory et al. (2010) describing a direct effect of 
GcMAF on human prostate cancer cells with inhibition 
of their proliferation and metastatic potential. It should 
be noticed, however, that this individual patient 
underwent also other types of immunotherapeutic 
approaches and therefore it is difficult to ascertain the 
exact role of each therapeutic approach. This type of 
interpretative difficulty is common in advanced cancer 
patients who are often simultaneously treated with 
different conventional and non-conventional approaches 
in order to achieve the best results. For example, a very 
recent report describes the effects of a combined 
immunotherapy comprising GcMAF-containing human 
serum, natural killer cell therapy, intravenous high-dose 
vitamin C, alpha lipoic acid and vitamin D3 
administered orally (Inui et al., 2013); it is evident that 
also in this case it is difficult to ascertain the individual 
merit of each treatment. 
Patient ID: 002-J., 62 Years Female 
Cancer:  Inflammatory Breast cancer.  Was diagnosed 
in April of 2012. Had two rounds of chemotherapy but 
was having pain still. The doctors did not give her much 
hope. She came to NCIM in November 2012. She 
received the granulocyte therapy plus stem cells from 
umbilical cord blood that have been programmed and 
primed. She has been injecting GcMAF once a week, 
Lynda Thyer et al. / American Journal of Immunology 9 (3): 78-84, 2013 
 
81 Science Publications
 
AJI 
Her cancer titers are very low. She has no more pain.  
We are monitoring her. She says that she feels no more 
symptoms. The cancer is going in remission. 
The results presented in this case are consistent with 
the original study by Yamamoto et al. (2008c) reporting 
that metastastic breast cancer patients treated with 
GcMAF obtained “eradication of the tumours. This 
therapeutic procedure resulted in no recurrence for more 
than 4 years.” (Yamamoto et al., 2008c). They are also 
consistent with the results by Pacini et al. (2012b) who 
described direct effects of GcMAF on human breast 
cancer cell proliferation and metastatic potential as well 
as on human breast cancer cell-stimulated neo-
angiogenesis (Pacini et al., 2012b). 
Patient ID: 003-P.H., 33 Years Male 
CFS:  He has been suffering from chronic fatigue 
syndrome for the last 14 years. Had been tested for every 
virus and Lymes (Borellia) but always was negative 
except HHV-6.  The titers were 1,200 in 2011 and 2012. 
Otherwise very healthy. His symptoms were fatigue but 
not bed ridden. Only needed to take a 30 to 60 min nap 
once or twice a day. The immune system was quite low. 
The Natural Killer cells were very low. His CD3 and 
CD4 immune cells were very very low. He had a cold 
every month and sometimes the colds would last 3 
months. Neutrophils, very low. Has been also diagnosed 
with fibromyalgia. Experiencing pain in the calves, thigh 
and arms as well as upper back. This, when stressed. 
Headaches when in the sun for a few hours. Suffered 
insomnia once in a while. He did not test for 
autoimmune disease. Started injecting GcMAF in 
October of 2012. He started not being tired after 16 
weeks of therapy. He only gets somewhat tied every 2-3 
weeks and just takes a 15 min nap and feels great. Only 
when stressed. After he finished the fourth GcMAF vial, 
his fibromyalgia pains are all gone.  The HHV-6 titers 
are nonexistent. The NK cell as well as the CD 3 and 4's 
are above normal. He is going to continue with the 
GcMAF injections until he finishes the 6 vials. He is 
ecstatic and so are we. 
The results presented in this case are consistent with 
those presented at the http://www.research1st.com/wp-
content/uploads/2011/10/IACFS.jpgbiennial meeting of 
the IACFS/ME held in Ottawa, Ontario, in 2011 
(http://www.research1st.com/2011/10/13/iacfsme-
summary/). They are also consistent with the very recent 
publication by Meirleir et al. (2013) demonstrating an 
association between human endogenous retroviruses and 
ME/CFS (Meirleir et al., 2013). Therefore, the results 
observed in this patient could be ascribed both to a 
reinforcement of the immune system with consequent 
improved control on viral infections and/or to a possible 
direct effect of GcMAF on neurons through cross-talk 
between GcMAF signalling and the VDR. 
Patient ID: 004-C.Y., 35 Years Female 
Multiple Sclerosis, with Lymes  (Borellia). In 
wheelchair for 7 years. Can not walk. Not to alert. Could 
not carry on a conversation well. Distracted. Twitches, 
stiffness. We have given her two treatments of cord 
blood stem cells. One every 7 months. She showed 
hardly any benefit with the first treatment but in October 
we added GcMAF to the treatment. She is doing 
amazing. She can be understood on the phone. The 
mother is taking her to her business and is conversing with 
the staff. I personally spoke to her 4 days ago. She carried 
on a conversation which she could not before. She started 
raising one leg then the other while lying in bed. Then steps 
with help. She is now standing by herself for almost an hour 
just helping herself holding on to a chair. One other 
symptom that she had was excessive shaking when she was 
stressed if people looked at her. This has almost 
disappeared. She is eating very well and is putting on make 
up. The Lymes is not showing in her test anymore. 
To our current knowledge, the results presented in 
this case have not yet been reported in other publications. 
It can be hypothesized that they can be ascribed to the 
stimulation of the immune system by GcMAF. 
Patient ID: 005-A.K., 67 Years Male 
Prostate Cancer: Metastasized to the liver, bone and 
brain. Jaundiced. The Alkaline Phosphatase was 398 
from the bone cancer. The PSA 1,600. The prostate as 
large as a grapefruit. Came to us in October 2012. He 
was treated with then rounds of granulocytes by 
apheresis and stem cells from the blood of three 
umbilical cords, Myschemals and CD34's as well as 
other more primitive stem cells derived from the 
Wharton's jelly of the three cords. He stayed in Mexico 
one month. Was detoxed, stabilized, given organic 
juices, choldronate to avoid more bone metastazis. He 
was given GcMAF. 50 injections twice a week until he 
left. He has been on the cancer protocol ever since and 
taking the GcMAF in synergy with the our cancer 
supplement protocol. We have sent him more MAF to 
continue the treatment.  I have finally spoken to the 
family last week after trying to reach them in Russia for 
a couple of weeks. His liver is clearing the cancer. The 
brain tumour is shrinking. The prostate is shrinking. He 
is alive and plans to continue with his GcMAF 
Lynda Thyer et al. / American Journal of Immunology 9 (3): 78-84, 2013 
 
82 Science Publications
 
AJI 
injections. He did have a clot in his leg but were able to 
take it out. His alkaline Phosphatase is now 80 because 
there is less bone destruction from the bone cancer. His 
PSA is 45 since last week. 
The results presented in this case are consistent with 
those observed in case #1. Also in this case the patient 
underwent also other types of non-conventional 
approaches and therefore it is difficult to ascertain the 
exact role of each approach. 
Patient ID: 006-H., 38 Years Male 
ALS or ALS-like symptoms (with Syphilis for 12 
years without knowing). He started having symptoms in 
December 2010. He started not being able to button his 
shirt buttons. Then unable to move his arms and not able 
to feed himself or go to the bathroom by himself. He 
then was not able to eat anything without drinking a 
fourth glass of water with each bite of food. He needed 
help climbing stairs so family members had to drag him 
upstairs to his room. He started choking on his food and 
was using a respirator off and on. We gave him 
autologous bone marrow stem cells that were 
programmed and stem cells from cord blood. He was 
treated with different antibiotics against the syphilis and 
given GcMAF. After the second stem cell treatment 30 
days later, he was able to hold an ice cream cone and 
feed himself. After the first stem cell treatment and 
continuing with his GcMAF treatment, he was walking 
with a cane and some times with help. 6 months after his 
treatments he started climbing up and down stairs just 
holding on to the rail. Then started doing work-outs on 
his treadmill. He is stable up until last week. He is not 
progressing. There is no more syphilis.  
The improvement of this patient can be ascribed to a 
combination of effects. The stimulation of the immune 
system by GcMAF could be responsible for the 
improvement of the infectious aspects of this complex 
situation. Also a direct effect of GcMAF on neurons 
cannot be ruled out. 
Patient ID: 007 - J.S., 11 Years Male 
Autistic. Would not play with other children. Would 
never look at people in the eyes. Withdrawn. Talked to 
himself mostly. Said incoherent things. As well all many 
other symptoms of autism. 
Started GcMAF treatment December 2012. After 
he had finished 12 weeks he started communicating 
with his mother. He is interacting with other children. 
He is not talking to himself very much. He is 
reciprocating and accepting hugs. 
The results presented in this case are fully consistent 
with those published by Bradstreet et al. (2012) who 
reported that “GcMAF therapy indicated substantial 
improvements in language, socialization and cognition” 
in autistic children. 
3. RESULTS AND DISCUSSION 
It is well assessed that GcMAF is effective against a 
variety of experimental and spontaneous tumours as well 
as against various aspects of neoplastic transformation 
in vitro (Yamamoto et al., 2008a; 2008b; 2008c; 
Nonaka et al., 2012; Gregory et al., 2010; Pacini et al., 
2012b). The clinical cases reported here are 
heterogeneous and describe patients with different types 
of tumours at different stages as well as patients with 
other pathologies. In many cases, patients underwent 
other treatments. In all cancer cases, GcMAF treatment 
was initiated at late stages of tumour progression since it 
is understandable that conventional therapies were 
preferred at earlier stages. In addition, since this is an 
open-label, non-controlled, retrospective analysis, 
caution must be employed when ascribing cause and 
effect to any treatment outcome. However, the response 
to GcMAF was robust and, even though any statistical 
analysis is inappropriate in such a heterogeneous 
recollection of clinical stories, the clinical improvement 
appears to be evident.  
A significant point that emerges from the study of the 
cases described above is the absence of any reported side 
effects associated with GcMAF injections in patients. 
This point, previously assessed also in autistic children 
(Bradstreet et al., 2012), assumes great importance when 
considering the administration of GcMAF in the context 
of the so called compassionate treatment of patients with 
advanced or incurable diseases. In fact, in many 
countries the absence of side effects is a pre-requisite for 
the compassionate administration of substances that have 
not yet been approved by local health authorities. It is 
obvious that these preliminary reports need a much 
longer follow-up in order to assess the best indications 
for GcMAF treatment.  
For example, referring to the role of GcMAF in 
oncology, GcMAF has been used, with encouraging 
results, in all types of cancers at all stages by physicians 
who use it as compassionate treatment. However, it can 
be hypothesized that certain histological types as well as 
certain definite stages of cancer might have a differential 
response to GcMAF. Also the patient’s genotype as far 
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as VDR gene polymorphisms are concerned, might 
influence the individual response to GcMAF. In fact, it 
was recently demonstrated that the degree of the 
response of normal human monocytes to GcMAF is 
associated with individual VDR genotypes (Pacini et al., 
2012a) and it can be hypothesized that also the response 
in terms of anti-neoplastic effects may be associated with 
such polymorphisms. Finally, it should be remembered 
that the prognosis for all types of cancers is dependent 
upon the nutritional and inflammatory status of the 
patient that can be monitored by the Prognostic 
Inflammatory and Nutritional Index (PINI) (Fabris et al., 
2012). The PINI score therefore could become part of the 
laboratory assessment during GcMAF treatment and 
together with Nagalase testing and VDR gene 
polymorphism determination, it could help monitor the 
response of each individual patient allowing adjustment 
of the dose and the frequency of administration in order 
to obtain the optimum results. 
The preliminary results reported here are consistent with 
the recent publication of Inui et al. (2013) who described 
three clinical cases successfully treated with a 
combination of therapies including subcutaneous or 
intramuscular injections of GcMAF-containing human 
serum (Hirota et al., 2013). However, at variance with 
their study, the results presented here were obtained with 
highly purified GcMAF instead of injecting human serum 
which was not purified using a vitamin D affinity column 
(Hirota et al., 2013). Therefore, we can conclude that the 
results that we observed are to be attributed to the highly 
purified GcMAF used in this study and not to other serum 
proteins that might have acted as confounding factors. 
3.1. Potential Conflicts of Interest   
DN is the CEO of Immuno Biotech, Ltd (the 
company isolating and purifying the GcMAF protein). 
However, DN had no knowledge of the therapies being 
used nor of the names of any patients whose data were 
being analyzed. Neither he, nor any employee of 
Immuno Biotech, Ltd had any knowledge of the clinical 
records or the patient names used in this study.  
4. CONCLUSION 
The observations reported here confirm and extend 
the results presented by several Authors on the role of 
GcMAF in different conditions and open the way to 
further studies aimed at assessing the precise role and 
indications of GcMAF in the immunotherapy of cancer 
and other chronic diseases. 
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